Efficacy of avelumab plus axitinib for advanced renal cell carcinoma as late-line therapy: A case report

Abstract

A 46-year-old man developed a right renal tumor with multiple lung and hilar lymph node metastases. Laparoscopic radical nephrectomy was performed, and clear cell renal cell carcinoma was diagnosed 6 years earlier. Despite the use of available systemic therapeutic agents, atelectasis in the right upper lobe due to a pulmonary hilar mass and brain metastases reduced his performance, and he was becoming terminally ill. After administration of avelumab plus axitinib as 9th-line therapy, significant shrinkage of the metastases and improvement in performance status were observed. This case indicates the possibility of using avelumab plus axitinib as late-line therapy.

Keywords

• Metastatic renal cell carcinoma
• Avelumab plus axitinib
• Late line
• IO-TKI combo
• Combination therapy